Ajit Elhance

441 total citations
10 papers, 270 citations indexed

About

Ajit Elhance is a scholar working on Immunology, Cell Biology and Infectious Diseases. According to data from OpenAlex, Ajit Elhance has authored 10 papers receiving a total of 270 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Immunology, 3 papers in Cell Biology and 2 papers in Infectious Diseases. Recurrent topics in Ajit Elhance's work include interferon and immune responses (2 papers), SARS-CoV-2 and COVID-19 Research (2 papers) and Immune cells in cancer (2 papers). Ajit Elhance is often cited by papers focused on interferon and immune responses (2 papers), SARS-CoV-2 and COVID-19 Research (2 papers) and Immune cells in cancer (2 papers). Ajit Elhance collaborates with scholars based in United States. Ajit Elhance's co-authors include S. Taniguchi, Naoki Oshimori, Sushil Kumar, Justin J. Leitenberger, J.D. Londino, Joseph S. Bednash, Daniela Farkas, László Farkas, Rama K. Mallampalli and Rama K. Mallampalli and has published in prestigious journals such as Science, Journal of Biological Chemistry and Frontiers in Immunology.

In The Last Decade

Ajit Elhance

9 papers receiving 268 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ajit Elhance United States 7 129 114 79 48 31 10 270
Hanxi Xiao United States 10 167 1.3× 109 1.0× 82 1.0× 47 1.0× 23 0.7× 19 309
Yuqin Yang China 10 75 0.6× 106 0.9× 79 1.0× 47 1.0× 58 1.9× 25 270
Fengxia Gao China 8 121 0.9× 129 1.1× 87 1.1× 59 1.2× 24 0.8× 17 311
Kelsey E. Huntington United States 12 91 0.7× 129 1.1× 100 1.3× 35 0.7× 47 1.5× 35 297
Wietske Pieters Netherlands 8 189 1.5× 190 1.7× 120 1.5× 65 1.4× 24 0.8× 9 370
Eileen Frenzel Germany 7 101 0.8× 142 1.2× 40 0.5× 45 0.9× 29 0.9× 7 275
Kebria Hezaveh Canada 8 215 1.7× 111 1.0× 105 1.3× 33 0.7× 21 0.7× 11 337
Yanghong Ni China 8 108 0.8× 148 1.3× 140 1.8× 67 1.4× 34 1.1× 9 328

Countries citing papers authored by Ajit Elhance

Since Specialization
Citations

This map shows the geographic impact of Ajit Elhance's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ajit Elhance with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ajit Elhance more than expected).

Fields of papers citing papers by Ajit Elhance

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ajit Elhance. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ajit Elhance. The network helps show where Ajit Elhance may publish in the future.

Co-authorship network of co-authors of Ajit Elhance

This figure shows the co-authorship network connecting the top 25 collaborators of Ajit Elhance. A scholar is included among the top collaborators of Ajit Elhance based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ajit Elhance. Ajit Elhance is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Elhance, Ajit, et al.. (2026). Sex differences in aortopathy, arteriopathy, and mortality in vascular Ehlers-Danlos syndrome. Journal of Vascular Surgery.
2.
Elhance, Ajit, et al.. (2025). Association of post-thrombotic syndrome with metabolic syndrome and inflammation - a systematic review. Frontiers in Immunology. 16. 1519534–1519534. 1 indexed citations
3.
Bednash, Joseph S., Daniela Farkas, Ajit Elhance, et al.. (2023). Inhibiting the Deubiquitinase UCHL1 Reduces SARS-CoV-2 Viral Uptake by ACE2. American Journal of Respiratory Cell and Molecular Biology. 68(5). 566–576. 8 indexed citations
4.
Farkas, Daniela, et al.. (2022). MicroID2: A Novel Biotin Ligase Enables Rapid Proximity-Dependent Proteomics. Molecular & Cellular Proteomics. 21(7). 100256–100256. 16 indexed citations
5.
Farkas, Daniela, et al.. (2022). The E3 ligase subunit FBXO45 binds the interferon-λ receptor and promotes its degradation during influenza virus infection. Journal of Biological Chemistry. 298(12). 102698–102698. 6 indexed citations
6.
Taniguchi, S., et al.. (2021). A mechanistic basis for the malignant progression of salivary gland tumors. iScience. 24(12). 103508–103508. 3 indexed citations
7.
Bednash, Joseph S., Valerian E. Kagan, Joshua A. Englert, et al.. (2021). Syrian hamsters as a model of lung injury with SARS-CoV-2 infection: Pathologic, physiologic, and detailed molecular profiling. Translational research. 240. 1–16. 40 indexed citations
8.
Mallampalli, Rama K., Ajit Elhance, Daniela Farkas, et al.. (2021). Interferon Lambda Signaling in Macrophages Is Necessary for the Antiviral Response to Influenza. Frontiers in Immunology. 12. 735576–735576. 24 indexed citations
9.
Taniguchi, S., et al.. (2020). Tumor-initiating cells establish an IL-33–TGF-β niche signaling loop to promote cancer progression. Science. 369(6501). 165 indexed citations
10.
Taniguchi, S., et al.. (2019). ADAP1 promotes invasive squamous cell carcinoma progression and predicts patient survival. Life Science Alliance. 2(6). e201900582–e201900582. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026